We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Retrospective Comparison of mFOLFOXIRI With XELOX/SOX as Neoadjuvant Chemotherapy for Locally Advanced Rectal Cancer.
- Authors
HIROYUKI KOADAMA; TETSUJI TERAZAWA; YASUNOBU ISHIZUKA; HIROKI YUKAMI; MASAHIKO AOKI; TAKAHIRO MIYAMOTO; TOSHIFUMI YAMAGUCHI; FUTUKARO SHIMAMOTO; TAKAYUKI KII; MASAHIRO GOTO; HIROKI HAMAMOTO; WATARU OSUMI; MASASHI YAMAMOTO; KEITARO TANAKA; JYUNJI OKUDA; KAZUHISA UCHIYAMA; KAZUHIDE HIGUCHI
- Abstract
Background/Aim: Neoadjuvant chemotherapy without radiation (NAC) shows favorable outcomes for locally advanced rectal cancer (LARC), however, the optimal regimen has not been determined yet. This study aimed to compare the efficacy and safety of oxaliplatin, irinotecan, folinic acid, and 5-fluorouracil (mFOLFOXIRI) with capecitabine/S-1 and oxaliplatin (XELOX/SOX) in rectal cancer patients. Patients and Methods: We retrospectively examined patients with LARC who received mFOLFOXIRI or XELOX/SOX as NAC. Results: Between January 2015 and July 2019, 49 patients received mFOLFOXIRI and 37 patients received XELOX/SOX. The pathological response rates (over two-thirds affected tumor area) were 36.7% and 40.5% in the mFOLFOXIRI and XELOX/SOX groups, respectively. Grade 3/4 neutropenia was experienced by 45.0% of the patients in the mFOLFOXIRI group and 8.0% in the XEOX/SOX group. Conclusion: Although pathological responses were comparable between two groups, mFOLFOXIRI tended to be more toxic compared to XELOX/SOX as NAC for LARC.
- Subjects
NEOADJUVANT chemotherapy; RECTAL cancer patients; FLUOROURACIL; OXALIPLATIN; FOLINIC acid
- Publication
In Vivo, 2021, Vol 35, Issue 2, p977
- ISSN
0258-851X
- Publication type
Article
- DOI
10.21873/invivo.12340